Correction to: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy (British Journal of Cancer, (2010), 103, 7, (1019-1024), 10.1038/sj.bjc.6605853)

Correction to: British Journal of Cancer Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy; https://doi.org/10.1038/sj.bjc.6605853; Article published online 14 September 2010 Following the original publication of the article, the authors identified an error in Table 2. Under KRAS status ‘Mutated’, TRG 3–4 originally read 51 (8.5); this should read 5 (18.5). (Table presented.) EGFR gene copy number, KRAS status, pathological response and downstaging EGFR/nuclei ratio CEP7 polisomy K-RAS status < 2.9 >2.9 p value <50 % >50 % p value Wild type Mutated p value Pathological response Assessable patients, n 113 27 110 30 114 27 TRG 4, n, (%) 15 (13.3) 6 (22.2) 0.19 14 (12.7) 7 (23.3) 0.13 19 (16.7) 2 (7.4) 0.18 TRG 3-4, n, (%) 36 (31.9) 9 (33.3) 0.53 36 (32.7) 9 (30.0) 0.48 40 (35.1) 5 (18.5) 0.07 Downstaging Assessable patients, n 109 29 105 33 111 28 Downstaging, n, (%) 65 (59.6) 19 (65.5) 0.36 68 (64.8) 16 (48.5) 0.07 69 (62.2) 16 (57.1) 0.39 The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.